Troubled Biotechs (UK Edition): Summit, Alizyme, ReNeuron
This article was originally published in The Pink Sheet Daily
Executive Summary
More than a third of UK biotechs are short of cash, and those that haven’t already found creative means of monetizing their assets have run out of time.
You may also be interested in...
UK Government Help For Life Sciences Sector Is Welcomed, But Still Not Enough
Therapeutic "clusters" are the next big idea, but unlikely to overshadow industry-academia tie-ups.
UK Government Help For Life Sciences Sector Is Welcomed, But Still Not Enough
Therapeutic "clusters" are the next big idea, but unlikely to overshadow industry-academia tie-ups.
UK Life Sciences Package Includes "Innovation Pass" To Skirt NICE
LONDON - The UK 's Life Sciences Blueprint is an urgent bid to kick-start a sector that's increasingly important to the nation's future growth - especially in the light of the downturn in financial services